Pharmaceuticals News & Press Release Distribution

ASCO 2022 | Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development

SUZHOU, China, and ROCKVILLE, Md., May 26, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its seven clinical abstracts selected by the ...

2022-05-27 10:02 2141

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels

- First clinical data demonstrating potential of SAFEbody technology platform to create best-in-class therapeutics - - Additional data from ongoing ADG126 clinical program to be presented in second half of 2022, including safety in combination with anti-PD-1 therapies - SAN DIEGO and SUZHOU, Chi...

2022-05-27 09:30 4905

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

- Uliledlimab appears safe and well-tolerated as a monotherapy and a combination therapy with toripalimab with no dose limiting toxicity - Encouraging efficacy signals were observed in a non-small cell lung cancer (NSCLC) patient cohort - Results indicate CD73 expression correlates with clini...

2022-05-27 05:01 2014

Portfolio Highlights: Clinical and Financing Updates of Anji, AIxplorerBio, Domain, VivaVision, ArrePath, QurAlis and Apeiron

SHANGHAI, May 26, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 month, our portfolio companies have had great progress. Anji Pharma Complete...

2022-05-26 23:53 2901

Menarini inaugurates new regional headquarters in Dubai, UAE

The pharmaceutical group, present in 140 countries in the world, aims to raise standard of patient healthcare across theMiddle East and Africa (MEA) region with innovative products and breakthrough research DUBAI, UAE, May 26, 2022 /PRNewswire/ -- Menarini, the leading Italian pharmaceutical gro...

2022-05-26 23:16 2926

Menarini inaugurates new regional headquarters in Dubai, UAE

US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD

Key Highlights: * US FDA has cleared Cynata's IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company * Phase 2 clinical study in aGvHD expected to commence subsequent to customary and satisfactory completion of ne...

2022-05-26 20:44 2142

Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer

SHANGHAI and WARREN, N.J., May 26, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage biotechnology company developing innovative medicines to treat cancer and liver diseases, today announced that two first patients have been dosed in the U.S. andChina, respectively, in a Phase Ib/III cli...

2022-05-26 20:27 1531

OLON ANNOUNCES THE CREATION OF A MAJOR CENTER OF RESEARCH AND DEVELOPMENT IN ITALY, THAT WILL GIVE RISE TO AN INNOVATIVE GLOBAL R&D MODEL

MILAN, May 26, 2022 /PRNewswire/ -- Olon, Leading API supplier, announces the creation of an R&D hub at its center inMilan, home to the Group's headquarters, paving the way for further major expansion and diversification of its expertise applied to the development of APIs for the CDMO and Generic...

2022-05-26 19:00 1707

111 to Announce First Quarter 2022 Unaudited Financial Results on June 16, 2022 - Conference Call to Follow

SHANGHAI, May 26, 2022 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results ...

2022-05-26 16:59 3121

Full-Life Technologies Completes $37 Million (USD) Series A Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Radiotechnology Production Platform

SHANGHAI and BRUSSELS, May 26, 2022 /PRNewswire/ -- Full-Life Technologies ("Full-Life") today announced it completed a$37 million (USD) Series A financing round to advance the development of its radiopharmaceutical oncology product pipeline and its radiotechnology production platform. The financ...

2022-05-26 12:00 1533

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia

TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based on data from the global, Phase 3 AGILE trial that demonstrated a statistically significant improvement in eve...

2022-05-26 08:07 2599

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia

TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based on data from the global, Phase 3 AGILE trial that demonstrated a statistically significant improvement in eve...

2022-05-26 04:45 1831

Golden Meditech Stem Cells Responds to Unfounded Accusations

HONG KONG, May 25, 2022 /PRNewswire/ -- On May 25, 2022, Golden Meditech Stem Cells (BVI) Company Limited (the "Company"), would like to respond to the accusations made against the Company in relation to the Company's enforcement of its rights under the Share Charge Agreement between the Company ...

2022-05-25 23:18 3275

Excelra Partners with HotSpot Therapeutics to Enhance Allosteric Drug Discovery Efforts

HYDERABAD, India and BOSTON, May 25, 2022 /PRNewswire/ -- Excelra, a leading global data and digital insights organization, today announced a partnership with HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for th...

2022-05-25 23:04 2839

The Centre for Probe Development and Commercialization expands into Asia and executes a development, manufacturing, and clinical supply agreement for 177Lu-PSMA (DGUL) With South Korea-based CellBion

HAMILTON, ON, May 25, 2022 /PRNewswire/ -- The Centre for Probe Development and Commercialization (CPDC) is pleased to announce the initiation of a development, manufacturing, and supply agreement withCellBion for Lu-177-radiolabelled PSMA (DGUL) therapeutic agent. Under the terms of the agreeme...

2022-05-25 21:00 1336

Seegene unveils '$12 PCR testing' initiative to help end COVID-19 pandemic

Includes asymptomatic testing at community-based facilities to prevent widespread transmissions Regular testing for COVID-19, flu, RSV crucial for staying safe as anti-virus restrictions are eased PCR tests will be priced affordably, made possible through Seegene's 20 years of expertise "Full ...

2022-05-25 19:00 2166

Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 25, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announcedthat it has successfully completed the dosing of first patient in phase I trial of B7H4x4-1BB bispecific antibody HBM7008 inAustralia. This study will evaluate ...

2022-05-25 17:42 1697

Brii Biosciences to be Added to MSCI China Small Cap Index

DURHAM, N.C. and BEIJING, May 25, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) today announced that it will be added to the MSCI China Small Cap Index, effective as ofHong Kong market close on May 31, 2022. ...

2022-05-25 08:00 4296

Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

* Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir. * The candidate is intended to be used for the treatment of SARS-CoV-2 and its variants, along with other coronaviruses. * ...

2022-05-25 05:00 2231

Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

ICP DAS - BMP will attend Medical Taiwan Expo 2022 in Taipei

TAIPEI, May 25, 2022 /PRNewswire/ -- ICP DAS - BMP (Biomedical Polymers), a Taiwanese medical TPU (thermoplastic polyurethane) supplier, will exhibit at Medical Taiwan 2022, an international medical, health, and care expo. The Medical Taiwan Expo 2022 will take place at the Taipei Nangang Exhibit...

2022-05-25 01:25 3477